Empreendimentos Pague Menos (PGMN3) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
16 Jun, 2025Company and market overview
Operates a unique healthcare platform in Brazil, combining strategic assets and a business model beyond traditional pharma retail.
Second largest pharmaceutical retail chain with 1,649 stores and presence in all Brazilian states.
Serves over 21 million active clients annually, with a strong brand in the North and Northeast.
Brazilian pharma retail market shows robust growth, driven by an aging population and resilient demand.
Market is highly fragmented, especially in lower-income segments, offering room for consolidation.
Competitive advantages
Nationwide footprint with 1,649 stores in 399 cities and 9 distribution centers.
Undisputed leadership in North and Northeast, with market shares of 21% and 16% respectively.
Focused on lower-income and expanded middle-class segments, capturing the largest addressable market.
Top-of-mind brands and robust customer engagement, with over 90% of sales identified and a strong loyalty program.
Strong governance with an experienced, diverse board and management team.
Strategic plan and growth initiatives
Vision to be Brazil’s best pharmaceutical retailer, offering complete health solutions and reducing healthcare access inequalities.
Strategic priorities include store expansion, omnichannel development, customer loyalty, Health Hub, and complementary businesses.
Opened 250+ stores organically since 2021 and acquired ~400 Extrafarma stores, targeting a minimum 20% IRR on expansion.
Completed integration of Extrafarma, achieving R$267 million in incremental EBITDA and consolidating regional leadership.
Omnichannel platform integrates stores, e-commerce, app, call center, and delivery, with fast innovation cycles.
Latest events from Empreendimentos Pague Menos
- Revenue and profit surged as growth accelerated, cash flow improved, and market share increased.PGMN3
Q2 202415 Jul 2026 - Record sales, margin gains, and cash flow driven by Extrafarma synergies and digital growth.PGMN3
Q3 202415 Jul 2026 - Record revenue, EBITDA, and digital sales drove margin gains and market share growth in 1Q25.PGMN3
Q1 202515 Jul 2026 - Record sales and digital growth drove higher margins, profit, and market share gains.PGMN3
Q2 202515 Jul 2026 - Record 18% revenue growth, 49.6% net income rise, and 6.7% market share in 3Q25.PGMN3
Q3 202515 Jul 2026 - Revenue up 14.4% YoY, net income quadrupled, and digital sales surged to 22.2% of total.PGMN3
Q1 202615 Jul 2026 - 2025 saw record revenue, EBITDA, and net income, with market share and digital sales at all-time highs.PGMN3
Q4 20257 Jul 2026 - Record sales, margin expansion, and synergy gains drive robust growth and deleveraging.PGMN3
Q4 20242 Jul 2026 - Nationwide healthcare platform drives growth through digital innovation and health services expansion.PGMN3
Investor Presentation3 Jul 2025